The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 11: 1483 - 1487

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.11.003

Feature Reports：Parkinson's disease

The correlations of serum Aβ1⁃42， P⁃Tau181， and Hcy levels with sleep disorders in Parkinson′s disease patients

  • Yanyun LI ,
  • Xueping CHEN ,
  • Peipei TIAN ,
  • Ting BAI ,
  • Qin GUO ,
  • Miao. GUO
Expand
  • *.Department of Rehabilitation，Xinjiang Production and Construction Corps Hospital，the Second Affiliated Hospital of Shihezi University Medical College，Urumqi 830002，China

Received date: 2023-09-25

  Online published: 2024-06-13

Fold

Abstract

Objective To investigate the correlations of serum Aβ1?42， P?Tau181， and Hcy levels with sleep disorders in patients with Parkinson's disease （PD）. Methods A total of 80 PD patients were divided into a normal sleep group （< 7 points） and a sleep disorder group （≥ 7 points） based on the evaluations with Pittsburgh Sleep Quality Index （PSQI）. Univariate and multivariate logistic regression analyses were performed to investigate the correlations between the levels of serum Aβ1-42， P-Tau181， and Hcy levels and sleep disorders. Receiver operating characteristic （ROC） curves were used to analyze the efficacy parameters of different indicators in predicting sleep disorders in those patients. Results Univariate and multivariate logistic regression analyses showed that serum Aβ1-42 and Hcy were protective and independent risk factors for sleep disorders in the PD patients， respectively （P < 0.05）. The predictive AUCs of serum Aβ1-42 and Hcy levels for sleep disorders in the PD patients were 0.757 （95% CI： 0.652 ~ 0.861） and 0.796 （95% CI： 0.688 ~ 0.905）， respectively. Conclusion The levels of serum Aβ1-42 and Hcy in PD patients are closely related to sleep disorders. Therefore， they can be used as predictive factors for clinical diagnosis of PD with sleep disorders.

Key words： Parkinson's disease; sleep disorder; Aβ1-42; P-Tau181; Hcy; correlation

Cite this article

Yanyun LI , Xueping CHEN , Peipei TIAN , Ting BAI , Qin GUO , Miao. GUO . The correlations of serum Aβ1⁃42， P⁃Tau181， and Hcy levels with sleep disorders in Parkinson′s disease patients[J]. The Journal of Practical Medicine, 2024 , 40(11) : 1483 -1487 . DOI: 10.3969/j.issn.1006-5725.2024.11.003

References

1 郁婷婷，黄卫，丁勇民，等. 临床及亚临床快速眼动睡眠期行为障碍与帕金森病认知功能的相关性［J］. 实用医学杂志，2017，33（20）：3387-3390. doi:10.3969/j.issn.1006-5725.2017.20.014
2 RYMAN S G， POSTON K L. MRI biomarkers of motor and non-motor symptoms in Parkinson's disease［J］. Parkinsonism Relat Disord， 2020， 73： 85-93. doi:10.1016/j.parkreldis.2019.10.002
3 BANG Y， LIM J， CHOI H J. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease： clues to early diagnosis and effective treatment［J］. Arch Pharm Res， 2021， 44（6）： 588-604. doi:10.1007/s12272-021-01337-3
4 TAXIMAIMAITI R， LUO X， WANG X P. Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease［J］. Curr Neuropharmacol， 2021， 19（12）： 2233-2249. doi:10.2174/1570159x19666210517115706
5 刘春风， 沈赟. 重视帕金森病睡眠障碍的规范管理［J］. 中华神经科杂志， 2019， 52（5）： 361-363. doi:10.3760/cma.j.issn.1006-7876.2019.05.001
6 YU Z， LI Y， the Parkinson's Progression Markers Initiative. Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson disease and scans without evidence of dopaminergic deficit［J］. Medicine （Baltimore）， 2021， 100（7）： e24837. doi:10.1097/md.0000000000024837
7 王小玲， 张霞， 程秋凤， 等. 老年帕金森病患者血清EGF， CysC， Aβ1~42表达变化及其与疾病分期， 认知障碍的相关性［J］. 中国老年学杂志， 2022， 42（11）： 2737-2740.
8 ANAMNART C， KITJARAK R. Effects of vitamin B12， folate， and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients： A randomized controlled study［J］. J Clin Neurosci， 2021， 88： 226-231. doi:10.1016/j.jocn.2021.03.047
9 吴海洋， 刘秀秀， 王颖， 等. 通督调神针刺对帕金森病模型小鼠线粒体自噬水平和多巴胺含量的影响［J］. 时珍国医国药， 2022， 33（6）： 1496-1500. doi:10.3969/j.issn.1008-0805.2022.06.65
10 袁宇浩， 徐岩. 睡眠障碍与帕金森病双向关系的研究进展［J］. 中华老年医学杂志， 2022， 41（2）： 220-224. doi:10.3760/cma.j.issn.0254-9026.2022.02.019
11 ZAHED H， ZUZUARREGUI J R P， GILRON R， et al. The Neurophysiology of Sleep in Parkinson's Disease［J］. Mov Disord， 2021， 36（7）： 1526-1542. doi:10.1002/mds.28562
12 WANG Z， ZHENG Y， CAI H， et al. Aβ1-42-containing platelet-derived extracellular vesicle is associated with cognitive decline in Parkinson's disease［J］. Front Aging Neurosci， 2023， 15： 1170663. doi:10.3389/fnagi.2023.1170663
13 肖成贤， 董滨， 张爱迪， 等. 血清α-syn， Aβ1-42，SSA在帕金森病患者中的表达及与认知功能损害的关系［J］. 现代生物医学进展， 2021， 21（14）： 2787-2791.
14 BA F， ZHOU Y， ZHOU J， et al. Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson's disease symptoms by regulating brain amyloid β1-42 level［J］. Mol Cell Biochem， 2019， 458（1/2）： 71-78. doi:10.1007/s11010-019-03531-w
15 KIMURA A M， TSUJI M， YASUMOTO T， et al. Myricetin prevents high molecular weight Aβ1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria［J］. Free Radic Biol Med， 2021， 171： 232-244. doi:10.1016/j.freeradbiomed.2021.05.019
16 GARRETT S L， MCDANIEL D， OBIDEEN M， et al. Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment［J］. JAMA Netw Open， 2019， 2（12）： e1917363. doi:10.1001/jamanetworkopen.2019.17363
17 GIBSON L L， POLLAK T A， HESLEGRAVE A， et al. Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease［J］. J Parkinsons Dis， 2022， 12（5）： 1527-1538. doi:10.3233/jpd-223182
18 BATZU L， ROTA S， HYE A， et al. Plasma p-tau181， neurofilament light chain and association with cognition in Parkinson's disease［J］. NPJ Parkinsons Dis， 2022， 8（1）： 154. doi:10.1038/s41531-022-00384-x
19 FU X Y， ZHANG Y C， DING C W， et al. Association between homocysteine and third ventricle dilatation， mesencephalic area atrophy in Parkinson's disease with cognitive impairment［J］. J Clin Neurosci， 2021， 90： 273-278. doi:10.1016/j.jocn.2021.06.006
20 ANAMNART C， KITJARAK R. Effects of vitamin B12， folate， and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients： A randomized controlled study［J］. J Clin Neurosci， 2021， 88： 226-231. doi:10.1016/j.jocn.2021.03.047
21 MURRAY L K， JADAVJI N M. The role of one-carbon metabolism and homocysteine in Parkinson's disease onset， pathology and mechanisms［J］. Nutr Res Rev， 2019， 32（2）： 218-230. doi:10.1017/s0954422419000106
22 丁俭， 章杰锦， 李俊毅， 等. 帕金森病血浆神经退行性蛋白与非运动症状的关系［J］.中华老年心脑血管病杂志， 2019， 21（5）： 506-510. doi:10.3969/j.issn.1009-0126.2019.05.015
23 邹瑜， 钟纯正， 郭春宣， 等. 胱抑素C与同型半胱氨酸在早期帕金森病患者血清中的水平及与睡眠障碍的关系［J］. 脑与神经疾病杂志， 2020， 28（2）： 96-100.
Options
Outlines

/

〈 〉